320 related articles for article (PubMed ID: 10068672)
21. Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal.
Ranheim EA; Kipps TJ
J Exp Med; 1993 Apr; 177(4):925-35. PubMed ID: 7681471
[TBL] [Abstract][Full Text] [Related]
22. IL-21 and CD40L signals from autologous T cells can induce antigen-independent proliferation of CLL cells.
Pascutti MF; Jak M; Tromp JM; Derks IA; Remmerswaal EB; Thijssen R; van Attekum MH; van Bochove GG; Luijks DM; Pals ST; van Lier RA; Kater AP; van Oers MH; Eldering E
Blood; 2013 Oct; 122(17):3010-9. PubMed ID: 24014238
[TBL] [Abstract][Full Text] [Related]
23. CD40 activation does not protect chronic lymphocytic leukemia B cells from apoptosis induced by cytotoxic T lymphocytes.
Chu P; Wierda WG; Kipps TJ
Blood; 2000 Jun; 95(12):3853-8. PubMed ID: 10845920
[TBL] [Abstract][Full Text] [Related]
24. CD40 activation: potential for specific immunotherapy in B-CLL.
von Bergwelt-Baildon M; Maecker B; Schultze J; Gribben JG
Ann Oncol; 2004 Jun; 15(6):853-7. PubMed ID: 15151939
[TBL] [Abstract][Full Text] [Related]
25. Transduction of CLL cells by CD40 ligand enhances an antigen-specific immune recognition by autologous T cells.
Mayr C; Kofler DM; Büning H; Bund D; Hallek M; Wendtner CM
Blood; 2005 Nov; 106(9):3223-6. PubMed ID: 16014560
[TBL] [Abstract][Full Text] [Related]
26. Chronic lymphocytic leukemia B cells can express CD40 ligand and demonstrate T-cell type costimulatory capacity.
Schattner EJ; Mascarenhas J; Reyfman I; Koshy M; Woo C; Friedman SM; Crow MK
Blood; 1998 Apr; 91(8):2689-97. PubMed ID: 9531577
[TBL] [Abstract][Full Text] [Related]
27. CD40 activation of BCP-ALL cells generates IL-10-producing, IL-12-defective APCs that induce allogeneic T-cell anergy.
D'Amico G; Vulcano M; Bugarin C; Bianchi G; Pirovano G; Bonamino M; Marin V; Allavena P; Biagi E; Biondi A
Blood; 2004 Aug; 104(3):744-51. PubMed ID: 15001471
[TBL] [Abstract][Full Text] [Related]
28. Chronic lymphocytic leukemia cells acquire regulatory B-cell properties in response to TLR9 and CD40 activation.
Ringelstein-Harlev S; Avivi I; Fanadka M; Horowitz NA; Katz T
Cancer Immunol Immunother; 2018 May; 67(5):739-748. PubMed ID: 29450641
[TBL] [Abstract][Full Text] [Related]
29. CD40-CD40L interactions provide "third-party" costimulation for T cell response against B7-1-transfected human breast tumor cells.
Pericle F; Epling-Burnette PK; Podack ER; Wei S; Djeu JY
J Leukoc Biol; 1997 Feb; 61(2):201-8. PubMed ID: 9021926
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of T cell/B cell interaction by B-CLL cells.
Kneitz C; Goller M; Wilhelm M; Mehringer C; Wohlleben G; Schimpl A; Tony HP
Leukemia; 1999 Jan; 13(1):98-104. PubMed ID: 10049067
[TBL] [Abstract][Full Text] [Related]
31. In vitro induction of myeloid leukemia-specific CD4 and CD8 T cells by CD40 ligand-activated B cells gene modified to express primary granule proteins.
Fujiwara H; Melenhorst JJ; El Ouriaghli F; Kajigaya S; Grube M; Sconocchia G; Rezvani K; Price DA; Hensel NF; Douek DC; Barrett AJ
Clin Cancer Res; 2005 Jun; 11(12):4495-503. PubMed ID: 15958635
[TBL] [Abstract][Full Text] [Related]
32. CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells.
Martens AWJ; Janssen SR; Derks IAM; Adams Iii HC; Izhak L; van Kampen R; Tonino SH; Eldering E; van der Windt GJW; Kater AP
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581054
[TBL] [Abstract][Full Text] [Related]
33. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug.
Ramsay AG; Johnson AJ; Lee AM; Gorgün G; Le Dieu R; Blum W; Byrd JC; Gribben JG
J Clin Invest; 2008 Jul; 118(7):2427-37. PubMed ID: 18551193
[TBL] [Abstract][Full Text] [Related]
34. Nonreplicating recombinant vaccinia virus expressing CD40 ligand enhances APC capacity to stimulate specific CD4+ and CD8+ T cell responses.
Feder-Mengus C; Schultz-Thater E; Oertli D; Marti WR; Heberer M; Spagnoli GC; Zajac P
Hum Gene Ther; 2005 Mar; 16(3):348-60. PubMed ID: 15812230
[TBL] [Abstract][Full Text] [Related]
35. Regulation of CD80/B7-1 and CD86/B7-2 molecule expression in human primary acute myeloid leukemia and their role in allogenic immune recognition.
Costello RT; Mallet F; Sainty D; Maraninchi D; Gastaut JA; Olive D
Eur J Immunol; 1998 Jan; 28(1):90-103. PubMed ID: 9485189
[TBL] [Abstract][Full Text] [Related]
36. Ex vivo generation of human anti-pre-B leukemia-specific autologous cytolytic T cells.
Cardoso AA; Seamon MJ; Afonso HM; Ghia P; Boussiotis VA; Freeman GJ; Gribben JG; Sallan SE; Nadler LM
Blood; 1997 Jul; 90(2):549-61. PubMed ID: 9226154
[TBL] [Abstract][Full Text] [Related]
37. Generation in vitro of B-cell chronic lymphocytic leukaemia-proliferative and specific HLA class-II-restricted cytotoxic T-cell responses using autologous dendritic cells pulsed with tumour cell lysate.
Goddard RV; Prentice AG; Copplestone JA; Kaminski ER
Clin Exp Immunol; 2001 Oct; 126(1):16-28. PubMed ID: 11678895
[TBL] [Abstract][Full Text] [Related]
38. Induction of chronic lymphocytic leukemia (CLL)-specific CD4- and CD8-mediated T-cell responses using RNA-transfected dendritic cells.
Müller MR; Tsakou G; Grünebach F; Schmidt SM; Brossart P
Blood; 2004 Mar; 103(5):1763-9. PubMed ID: 14615377
[TBL] [Abstract][Full Text] [Related]
39. Human Ly9 (CD229) as novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (B-CLL) recognized by autologous CD8+ T cells.
Bund D; Mayr C; Kofler DM; Hallek M; Wendtner CM
Exp Hematol; 2006 Jul; 34(7):860-9. PubMed ID: 16797413
[TBL] [Abstract][Full Text] [Related]
40. Improving CLL Vγ9Vδ2-T-cell fitness for cellular therapy by ex vivo activation and ibrutinib.
de Weerdt I; Hofland T; Lameris R; Endstra S; Jongejan A; Moerland PD; de Bruin RCG; Remmerswaal EBM; Ten Berge IJM; Liu N; van der Stelt M; Faber LM; Levin MD; Eldering E; Tonino SH; de Gruijl TD; van der Vliet HJ; Kater AP
Blood; 2018 Nov; 132(21):2260-2272. PubMed ID: 30213872
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
